Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
Portfolio Pulse from
Compugen Ltd. has been granted a new U.S. patent for the use of its COM902 antibody in combination with anti-PD-1 and anti-PVRIG antibodies for cancer treatment, enhancing its intellectual property portfolio.
November 27, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Compugen Ltd. has received a new U.S. patent for its COM902 antibody in combination with anti-PD-1 and anti-PVRIG antibodies, potentially enhancing its competitive edge in cancer immunotherapy.
The new patent for COM902 in combination with other antibodies could enhance Compugen's competitive position in the cancer immunotherapy market, potentially leading to increased investor interest and a positive impact on stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100